AIFM2 and neoplasm: The TCGA database revealed that poorer survival of patients with higher expression of FSP1 (AIFM2) (Figure 1E) and that FSP1 is highly abnormally expressed in head and neck cancer tissues and expression increases with tumor progression (Figure 1F).